173 related articles for article (PubMed ID: 22640008)
1. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.
Toze CL; Dalal CB; Nevill TJ; Gillan TL; Abou Mourad YR; Barnett MJ; Broady RC; Forrest DL; Hogge DE; Nantel SH; Power MM; Song KW; Sutherland HJ; Smith CA; Narayanan S; Young SS; Connors JM; Shepherd JD
Br J Haematol; 2012 Jul; 158(2):174-185. PubMed ID: 22640008
[TBL] [Abstract][Full Text] [Related]
2. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
3. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
5. Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K; Iacobelli S; Leiblein S; Eisfeld AK; Pfrepper C; Heyn S; Vucinic V; Franke GN; Krahl R; Fricke S; Becker C; Pönisch W; Behre G; Niederwieser D; Lange T
Leuk Lymphoma; 2014 Jun; 55(6):1274-80. PubMed ID: 23964650
[TBL] [Abstract][Full Text] [Related]
6. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
Helbig G; Spałek A; Wieczorkiewicz-Kabut A; Markiewicz M; Kopera M; Zielińska P; Woźniczka K; Kopińska A; Grygoruk-Wiśniowska I; Koclęga A
Ann Hematol; 2019 Jun; 98(6):1477-1483. PubMed ID: 30919074
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
Machaczka M; Johansson JE; Remberger M; Hallböök H; Malm C; Lazarevic VLj; Wahlin A; Omar H; Juliusson G; Kimby E; Hägglund H
Leuk Lymphoma; 2012 Sep; 53(9):1699-705. PubMed ID: 22335529
[TBL] [Abstract][Full Text] [Related]
9. Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.
Huang SJ; Chan J; Bruyère H; Allan LL; Gerrie AS; Toze CL
Leuk Res; 2019 Sep; 84():106193. PubMed ID: 31325731
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
11. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
14. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
15. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
16. [Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia (CLL) patients with the aberration of p53 gene].
Wang L; Miao K; Fan L; Xu J; Wu H; Li J; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):308-12. PubMed ID: 27093994
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
18. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
Toze CL; Galal A; Barnett MJ; Shepherd JD; Conneally EA; Hogge DE; Nantel SH; Nevill TJ; Sutherland HJ; Connors JM; Voss NJ; Kiss TL; Messner HA; Lavoie JC; Forrest DL; Song KW; Smith CA; Lipton J
Bone Marrow Transplant; 2005 Nov; 36(9):825-30. PubMed ID: 16151430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
